Fig. 7

Effects of each CGRP mAb on HIT-6 score. Temporal profiles of HIT-6 score in patients treated with galcanezumab (n = 31, A), fremanezumab (n = 24, B), and erenumab (n = 13, C). Data are shown as mean ± SD. Statistical analysis was performed using one-way ANOVA with Dunnett’s post hoc test for galcanezumab and erenumab and the Kruskal–Wallis test with Dunn’s post hoc test for erenumab. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. D Overlay line graph depicting the temporal profiles of each CGRP mAb. Between-group comparisons at each timepoint were performed with Dunnett’s post hoc test. #p < 0.05, galcanezumab vs. fremanezumab